Irbesartan Eg

Irbesartan, the active ingredient in Irbesartan Eg, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for systemic use. It is indicated for the management of hypertension and for slowing the progression of diabetic nephropathy in adult patients, and is marketed in the European Union.

GNH USA supplies Irbesartan Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent product quality, regulatory adherence, and reliable logistics to meet the needs of healthcare providers across multiple regions.

Irbesartan acts on the renin‑angiotensin system to control blood pressure and protect kidney function.

Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. Diabetic nephropathy: slows progression of renal impairment in patients with type 2 diabetes. Proteinuria: decreases urinary protein excretion, supporting kidney health.

Irbesartan may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Upper respiratory tract infection: nasopharyngitis or mild cough.

Serious or Rare Side Effects: - Hyperkalemia: elevated blood potassium levels, potentially dangerous. - Acute kidney injury: sudden decline in renal function. - Angioedema: swelling of face, lips, tongue, or airway. - Hepatic dysfunction: abnormal liver enzymes or hepatitis.

When prescribing Irbesartan, clinicians should consider several safety aspects.

Monitor blood pressure: ensure adequate control without excessive hypotension. Assess renal function: check serum creatinine and eGFR before and during therapy. Check serum potassium: avoid hyperkalemia, especially with potassium‑sparing diuretics. Contraindicated in: patients with known hypersensitivity to Irbesartan or other ARBs. Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Irbesartan can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal impairment and hyperkalemia. - Potassium‑supplementing agents or potassium‑sparing diuretics: may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: additive risk of hypotension, hyperkalemia, renal dysfunction. - Diuretics (especially thiazides): may enhance antihypertensive response; monitor electrolytes.